Nacimbio to Supply Drugs for Patients with Hemophilia

Nacimbio to Supply Drugs for Patients with Hemophilia

Nacimbio JSC, the pharmaceutical subsidiary of Rostec State Corporation, has concluded four new contracts with the Russian Ministry of Healthcare for the supply of blood products in 2018 as part of the ‘Seven Nosologies’ Programme. The contracts totaling over RUB 1.7 bn stipulate the supply of drugs in the amount of more than 222 million IU - blood-coagulation factors VIII, IX, blood-coagulation factor VIII + Willebrand factor. Previously, the Ministry purchased from the pharmaceutical holding almost 20 million units of the Anti-inhibitor Coagulant Complex amounting to more than RUB 1 bn.  

For the first time this year, Nacimbio employs innovative technological and logistical solutions for cold-chain drug transportation, which minimises violations of storage and transportation conditions for temperature-dependent complex goods.

In particular, it uses the most advanced thermal containers that can continuously maintain the required temperature conditions twice as long as the majority of solutions available in the market - up to 7 days. The holding has already used these new solutions to supply the Anti-inhibitor Coagulant Complex, which was consigned to the Healthcare Ministry recipients prior to the scheduled date – on 10 May 2018, i.e. 10 days ahead of the schedule. 

The Company is also implementing a new modern system for monitoring goods traffic and temperature in containers, with sensors transmitting online information on the status and location of goods. The system will enable to increase supply efficiency, promptly respond to any irregularities, provide the customer with the up-to-the-minute information on the movement of cargo with drugs.

“The Company accumulated a considerable experience in large nationwide supplies. It acquired expertise in logistics technologies, having implemented a range of innovations, as well as in cooperation with partners and suppliers as a result of consistent establishment and expansion of business contacts in the industry. This allows us to ensure uninterrupted supplies of necessary drugs for the healthcare system and patients, including drugs that should be transported under complicated conditions,” said Andrey Zagorskiy, Nacimbio Director General. 

According to the abovementioned contracts, the shipment of blood-coagulation factors VIII and IX will be completed by the 1st of July and the shipment of factor VIII + Willebrand factor – until the 1st of August.

In 2017, Russia’s blood product market was estimated at 22.7 bn rubles. The share of plasma factors in the total volume of blood-coagulation factor purchases amounted to 57%. According to the register of the Ministry of Healthcare of the Russian Federation, the total number of patients with hemophilia in the previous year amounted to 9,400 people - the number of patients increased by 28% from 2007 to 2017.

In March 2018, the Government of the Russian Federation again recognised Nacimbio JSC as the sole supplier of medicinal products derived from human and animal blood plasma, the purchases of which are performed by federal institutions and their subordinate authorities in 2018 and 2019. From 2016 to 2017, performing the single-supplier function, Nacimbio supplied more than 800 million IU of blood plasma products (equivalent to 1 million packages) for the country’s needs in the required timescale and in full volume.